We are developing a product portfolio of novel targeted therapeutics for defined neurodegenerative disease populations. Our research programs are focused on examining the underlying molecular processes of neurodegenerative diseases to identify targets and biomarkers for efficacy and patient selection.
Informed by the latest genetics research and advances in human disease understanding, target discovery is focusing on areas of biology that increase an individual’s vulnerability to developing a neurodegenerative disease. We are currently exploring some of the common neuropathological mechanisms that could yield new targets, these include mitochondrial quality control, proteostasis and neuroinflammation.
We are investigating a range of neurodegenerative diseases including Alzheimer’s dementia, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and frontotemporal dementia. We will also examine orphan CNS diseases with a clear genetic association, as well as epigenetic targets.